VCYT Quote, Financials, Valuation and Earnings

Insight Molecular Diagnostics, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of -4174.62%. Veracyte, Inc.'s return on equity of 2.52% beat Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03%.

Veracyte, Inc. has a consensus price target of $47.10, signalling downside risk potential of -1.36%. On the other hand Insight Molecular Diagnostics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 31.09%. Given that Insight Molecular Diagnostics, Inc. has higher upside potential than Veracyte, Inc., analysts believe Insight Molecular Diagnostics, Inc. is more attractive than Veracyte, Inc..

Veracyte, Inc. has a beta of 1.829, which suggesting that the stock is 82.869% more volatile than S&P 500. In comparison Insight Molecular Diagnostics, Inc. has a beta of 1.183, suggesting its more volatile than the S&P 500 by 18.332%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte, Inc. pays -- of its earnings as a dividend. Insight Molecular Diagnostics, Inc. pays out -- of its earnings as a dividend.

Veracyte, Inc. quarterly revenues are $131.9M, which are larger than Insight Molecular Diagnostics, Inc. quarterly revenues of $260K. Veracyte, Inc.'s net income of $19.1M is higher than Insight Molecular Diagnostics, Inc.'s net income of -$10.9M. Notably, Veracyte, Inc.'s price-to-earnings ratio is 125.79x while Insight Molecular Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 7.67x versus 32.49x for Insight Molecular Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of -774.52%. Veracyte, Inc.'s return on equity of 2.52% beat ProPhase Labs, Inc.'s return on equity of -90.24%.

Veracyte, Inc. has a consensus price target of $47.10, signalling downside risk potential of -1.36%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 10099.56%. Given that ProPhase Labs, Inc. has higher upside potential than Veracyte, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Veracyte, Inc..

Veracyte, Inc. has a beta of 1.829, which suggesting that the stock is 82.869% more volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.657, suggesting its less volatile than the S&P 500 by 165.684%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte, Inc. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.

Veracyte, Inc. quarterly revenues are $131.9M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. Veracyte, Inc.'s net income of $19.1M is higher than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, Veracyte, Inc.'s price-to-earnings ratio is 125.79x while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 7.67x versus 0.93x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Exagen, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of -41.1%. Veracyte, Inc.'s return on equity of 2.52% beat Exagen, Inc.'s return on equity of -140.03%.

Veracyte, Inc. has a consensus price target of $47.10, signalling downside risk potential of -1.36%. On the other hand Exagen, Inc. has an analysts' consensus of $15.43 which suggests that it could grow by 111.93%. Given that Exagen, Inc. has higher upside potential than Veracyte, Inc., analysts believe Exagen, Inc. is more attractive than Veracyte, Inc..

Veracyte, Inc. has a beta of 1.829, which suggesting that the stock is 82.869% more volatile than S&P 500. In comparison Exagen, Inc. has a beta of 1.801, suggesting its more volatile than the S&P 500 by 80.089%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exagen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte, Inc. pays -- of its earnings as a dividend. Exagen, Inc. pays out -- of its earnings as a dividend.

Veracyte, Inc. quarterly revenues are $131.9M, which are larger than Exagen, Inc. quarterly revenues of $17.2M. Veracyte, Inc.'s net income of $19.1M is higher than Exagen, Inc.'s net income of -$7.1M. Notably, Veracyte, Inc.'s price-to-earnings ratio is 125.79x while Exagen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 7.67x versus 2.32x for Exagen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XWELL, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of -2.87%. Veracyte, Inc.'s return on equity of 2.52% beat XWELL, Inc.'s return on equity of -224.93%.

Veracyte, Inc. has a consensus price target of $47.10, signalling downside risk potential of -1.36%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 775%. Given that XWELL, Inc. has higher upside potential than Veracyte, Inc., analysts believe XWELL, Inc. is more attractive than Veracyte, Inc..

Veracyte, Inc. has a beta of 1.829, which suggesting that the stock is 82.869% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.697%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.

Veracyte, Inc. quarterly revenues are $131.9M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. Veracyte, Inc.'s net income of $19.1M is higher than XWELL, Inc.'s net income of -$211K. Notably, Veracyte, Inc.'s price-to-earnings ratio is 125.79x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 7.67x versus 0.15x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.